Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris
Other stock markets
 11:35:16 2024-05-17 am EDT 		After market 02:19:36 pm
14.2 EUR +3.65% Intraday chart for MedinCell S.A. 14.2 0.00%
May. 15 Medincell: share price falls after disappointing clinical study CF
May. 15 Transcript : MedinCell S.A. - Special Call

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medincell: share price falls after disappointing clinical study
CF
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
BU
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
CI
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
AQ
Medincell: share price rises on resumption of trading
CF
CAC40: remains in green in a neglected market
CF
Medincell: positive results in schizophrenia
CF
Medincell Listing Temporarily Suspended on Euronext Paris
MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
RE
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
BU
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
CI
CAC40: in green, builds on previous day's momentum
CF
MedinCell S A : Inside Information / Other news releases
PU
Medincell: listing suspended pending a press release
CF
Medincell announces the suspension of listing of its shares on Euronext Paris
BU
Medincell: share price rises following agreement with AbbVie
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW